Obermatt
See Similar Stocks →

Ardelyx

NMQ:ARDX · US0396971071
BiotechnologyMedium

360

82
EV / EBIT31
Price / Owner Earnings88
Owner Earnings Yield1
Dividend Yield1
Price/Sales91
EV / Gross Profit91
Price/Book20
Return on Capital71
Cash Return on Capital51
Return on Equity56
EBIT Margin47
Gross Profitability95
Accruals44
Owner Earnings Margin65
Sales growth63
Profit growth78
Reinvestment5
Price momentum60
Debt load13
Refinancing95
Debt Payback1
Liquidity69
Analyst ratings77
Opinion Changes50
Price Target Upside98
Market mood76
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Ardelyx clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGM
Founded2007
Employees432
Websiteardelyx.com
ISINUS0396971071
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Chronic DiseasesNephrologyGastroenterologyBiotechnologyHealth CareMedical

Description

Ardelyx, Inc. (Ardelyx) operates as a commercial-stage biopharmaceutical company. The company focuses on the development and commercialization of medicines that meet significant unmet medical needs. The company markets two therapies from the active…

Analysis

Middle-of-the-road

Ardelyx, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 10/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
32
2026

All-time high

39

Mar 2026

All-time low

32

Jun 2026

Average rank

36

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
91
—
—
—
Price/Earnings
6
—
—
—
Price/Book
20
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
7
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Ardelyx with its peers
Jade Biosciences
NAQ:JBIO
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Unicycive Therapeutics
NAQ:UNCY
85
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Cytokinetics
NSQ:CYTK
13
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
RAPT Therapeutics
NMQ:RAPT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Atea Pharmaceuticals
NSQ:AVIR
5
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Xenon Pharmaceuticals
NMQ:XENE
28
CountryCanada
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →